[
    [
        {
            "time": "",
            "orginal_text": "医药行业重大事项点评：国务院发布药品带量采购意见 应采尽采 范围更广",
            "features": {
                "keywords": [
                    "药品带量采购",
                    "国务院",
                    "政策",
                    "范围更广"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药行业重大事项点评：国务院发布药品带量采购意见 应采尽采 范围更广",
            "scores": {
                "News_content": "医药行业重大事项点评：国务院发布药品带量采购意见 应采尽采 范围更广",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 10,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业：药品集采常态化 坚定拥抱医药创新",
            "features": {
                "keywords": [
                    "药品集采",
                    "常态化",
                    "医药创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药生物行业：药品集采常态化 坚定拥抱医药创新",
            "scores": {
                "News_content": "医药生物行业：药品集采常态化 坚定拥抱医药创新",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "高瓴资本概念股普遍调整，凯莱英、健康元、金域医学、海正药业跌幅居前",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "调整",
                    "凯莱英",
                    "健康元",
                    "金域医学",
                    "海正药业"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "高瓴资本概念股普遍调整，凯莱英、健康元、金域医学、海正药业跌幅居前",
            "scores": {
                "News_content": "高瓴资本概念股普遍调整，凯莱英、健康元、金域医学、海正药业跌幅居前",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
            "features": {
                "keywords": [
                    "CRO",
                    "CDMO",
                    "行情",
                    "长坡厚雪",
                    "未来可期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
            "scores": {
                "News_content": "中泰证券--医药生物行业周报：CRO/CDMO行情将如何延续？长坡厚雪，未来可期【行业研究】",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]